Belgium· BE-AMP-SAM585457-00
Ponvory 2 mg
A ponesimod product containing ponesimod, registered in Belgium by Laboratoires Juvise Pharmaceuticals. The same ATC class is registered in 11 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Ponesimod is registered in 11 of 19 countries.
Countries holding a registration under ATC L04AE04 (ponesimod), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 7 of them publish a price we can compare per daily dose
Ponesimod · ATC L04AE04
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Italyprice
- Netherlands
- Norwayprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of ponesimod costs, country by country.
Normalised to the WHO defined daily dose (20 mg), so markets compare like for like.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Ponesimod · price per daily dose (20 mg)
USD · FX 28 Sept 2026
- IT Italy$69.77
- CH Switzerland$69.06
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Ponesimod
- Manufacturer
- Laboratoires Juvise Pharmaceuticals
- Country
- Belgium (BE)
- ATC code
- L04AE04
- ATC class
- Ponesimod
- Defined daily dose
- 20 mg, O
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 2
1 priced- be_apb4359188EUR 634.93
- be_apb7733793
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Ponesimod in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SwitzerlandPonvory 2 mg, FilmtablettenMedius AG
- IrelandPonvory 2 mg+3 mg+4 mg+5 mg+6 mg+7 mg+8 mg+9 mg+10 mg film-coated tabletsLaboratoires Juvise Pharmaceuticals
- NorwayPonvoryLABORATOIRES JUVISE PHARMACEUTICALS
- United KingdomPonvory 10mg tabletsJuvise Pharmaceuticals
- CzechiaPONVORYLaboratoires Juvisé Pharmaceuticals, Villeurbanne
- IcelandPonvoryLABORATOIRES JUVISE PHARMACEUTICALS
- ItalyPONVORY*14 cpr rivestite confezione di inizio trattamentoLAB.JUVISE' PHARMACEUTICALS
- NetherlandsPonvory 2 mg + 3 mg + 4 mg + 5 mg + 6 mg + 7 mg + 8 mg + 9 mg + 10 mg filmomhulde tablettenLaboratoires Juvise Pharmaceuticals
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Ponvory
- Liechtenstein · Ponvory
- Norway · Ponvory
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/02be1b86-efe0-44b4-bf7d-6cfdf31fea31 GET /v1/drugs/02be1b86-efe0-44b4-bf7d-6cfdf31fea31?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Film-coated tablet",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Ponvory 2 mg",
"name_fr": "Ponvory 2 mg",
"name_nl": "Ponvory 2 mg",
"amp_code": "SAM585457-00",
"strengths": [
"2.0000",
"2.0000",
"23.0000",
"3.0000",
"3.0000",
"22.0000",
"4.0000",
"4.0000",
"21.0000",
"5.0000",
"5.0000",
"118.0000"
],
"pack_count": 1,
"substances": [
"Ponesimod",
"Lactose",
"Sodium Laurilsulfate"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Ponesimod",
"authorisation_numbers": [
"EU/1/21/1550/001"
]
}See everything about ponesimod.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.